The association of uncoupling proteins 1, 2, and 3 with weight loss variability after bariatric surgery: a systematic review

2020 ◽  
Vol 16 (11) ◽  
pp. 1858-1868 ◽  
Author(s):  
Mayara Souza de Oliveira ◽  
Pâmela Sachs Nique ◽  
Daisy Crispim ◽  
Bianca Marmontel de Souza
2017 ◽  
Vol 76 (11) ◽  
pp. 1870-1882 ◽  
Author(s):  
Sabrina M Nielsen ◽  
Else M Bartels ◽  
Marius Henriksen ◽  
Eva E Wæhrens ◽  
Henrik Gudbergsen ◽  
...  

ObjectivesWeight loss is commonly recommended for gout, but the magnitude of the effect has not been evaluated in a systematic review. The aim of this systematic review was to determine benefits and harms associated with weight loss in overweight and obese patients with gout.MethodsWe searched six databases for longitudinal studies, reporting the effect of weight loss in overweight/obese gout patients. Risk of bias was assessed using the tool Risk of Bias in Non-Randomised Studies of Interventions. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation.ResultsFrom 3991 potentially eligible studies, 10 were included (including one randomised trial). Interventions included diet with/without physical activity, bariatric surgery, diuretics, metformin or no intervention. Mean weight losses ranged from 3 kg to 34 kg. Clinical heterogeneity in study characteristics precluded meta-analysis. The effect on serum uric acid (sUA) ranged from −168 to 30 μmol/L, and 0%–60% patients achieving sUA target (<360 μmol/L). Six out of eight studies (75%) showed beneficial effects on gout attacks. Two studies indicated dose–response relationship for sUA, achieving sUA target and gout attacks. At short term, temporary increased sUA and gout attacks tended to occur after bariatric surgery.ConclusionsThe available evidence is in favour of weight loss for overweight/obese gout patients, with low, moderate and low quality of evidence for effects on sUA, achieving sUA target and gout attacks, respectively. At short term, unfavourable effects may occur. Since the current evidence consists of a few studies (mostly observational) of low methodological quality, there is an urgent need to initiate rigorous prospective studies (preferably randomised controlled trials).Systematic review registrationPROSPERO, CRD42016037937.


2019 ◽  
Vol 29 (10) ◽  
pp. 3371-3384 ◽  
Author(s):  
Alejandro Carretero-Ruiz ◽  
María del Carmen Olvera-Porcel ◽  
Iván Cavero-Redondo ◽  
Celia Álvarez-Bueno ◽  
Vicente Martínez-Vizcaíno ◽  
...  

Author(s):  
Rawan ElAbd ◽  
Osama A. Samargandi ◽  
Khalifa AlGhanim ◽  
Salma Alhamad ◽  
Sulaiman Almazeedi ◽  
...  

2018 ◽  
Vol 14 (3) ◽  
pp. 413-422 ◽  
Author(s):  
Felipe E. Pedroso ◽  
Federico Angriman ◽  
Atsushi Endo ◽  
Hormuzdiyar Dasenbrock ◽  
Alessandra Storino ◽  
...  

2016 ◽  
Vol 4 (10) ◽  
pp. 1159-1164
Author(s):  
Odai Albahli ◽  
◽  
Mohamed Alharbi ◽  
Sayer Alotaibi.

2020 ◽  
Vol 34 (6) ◽  
pp. 2410-2428 ◽  
Author(s):  
Yan Mei Goh ◽  
Nicole Ellen James ◽  
En Lin Goh ◽  
Achal Khanna

Abstract Background Weight regain following primary bariatric surgery is attributed to anatomical, behavioural and hormonal factors. Dilation of the gastrojejunal anastomosis is a possible cause of weight regain after roux-en-Y gastric bypass (RYGB). However, surgical revision has significant risks with limited benefits. Endoluminal procedures have been suggested to manage weight regain post-surgery. This systematic review aims to assess efficacy of endoluminal procedures. Methods Studies where endoluminal procedures were performed following primary bariatric surgery were identified. Main outcome measures were mean weight loss pre- and post-procedure, excess weight loss, recurrence rates, success rates and post-procedure complications. Results Twenty-six studies were included in this review. Procedures identified were (i) endoluminal plication devices (ii) other techniques e.g. sclerotherapy, mucosal ablation, and Argon Plasma Coagulation (APC) and (iii) combination therapy involving sclerotherapy/mucosal ablation/APC and endoscopic OverStitch device. Endoluminal plication devices show greatest initial weight loss within 12 months post-procedure, but not sustained at 18 months. Only one study utilising sclerotherapy showed greater sustained weight loss with peak EWL (19.9%) at 18 months follow-up. Combination therapy showed the greatest sustained EWL (36.4%) at 18 months. Endoluminal plication devices were more successfully performed in 91.8% of patients and had lower recurrence rates (5.02%) compared to sclerotherapy and APC, with 46.8% success and 21.5% recurrence rates. Both procedures demonstrate no major complications and low rates of moderate complications. Only mild complications were noted for combination therapy. Conclusions The paucity of good quality data limits our ability to demonstrate and support the long-term efficacy of endoluminal techniques in the management of weight regain following primary bariatric surgery. Future work is necessary to not only clarify the role of endoluminal plication devices, but also combination therapy in the management of weight regain following primary bariatric surgery.


Sign in / Sign up

Export Citation Format

Share Document